Healthcare

Radiopharm Theranostics Limited (ASX:RAD) is a clinical-stage radiotherapeutics company developing radiopharmaceutical products for diagnostic and therapeutic applications in oncology. The company’s pipeline includes peptide, small molecule and monoclonal antibody technologies targeting areas of high unmet medical need. Recent progress has centred on RAD101, a …

Clover Corporation (ASX:CLV) has reported recordRevenueand a sharply higher profit for the 2026 financial year, while confirming that long-serving chairman Rupert Harrington will step down from the board at this year's annual general meeting. The nutritional ingredients maker lodged its full-year results, results presentation …

Paragon Care Limited (ASX:PGC) has released its audited financial statements for the year ended 30 June 2026, confirming that its bottom-line result is unchanged from the preliminary figures it reported to the market in August. The healthcare wholesaler, distributor and manufacturer lodged its FY26 …

Invion Limited (ASX:IVX) is a clinical-stage life-science company developing Photosoft™, a Next Generation Photodynamic Therapy platform for cancer, infectious diseases and other medical applications. The company holds global licensing rights for Photosoft and is progressing clinical, pre-clinical andPartnershipprograms designed to evaluate the technology across …

Firebrick Pharma Limited (ASX:FRE) is a healthcare company focused on developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). Its lead product, Nasodine® Nasal Spray, is being introduced across international markets, supported by a broader Nasodine product portfolio. During FY26, Firebrick progressed fromResearch …

Holista Colltech Limited (ASX:HCT) reported continued progress across its health and wellness businesses during the half year ended 30 June 2026, with revenue growth supported by its Dietary Supplements division and ongoing product development activities.Group revenue increased 3.6% to $2.99 million compared with $2.89 …

Argenica Therapeutics Limited (ASX:AGN) continued advancing its neuroprotective therapeutic development program during FY26, with progress across clinical research, regulatory activities and preclinical studies.The company reported revenue of $5.70 million for the year ended 30 June 2026, representing a 53% increase compared with the previous …